{
    "id": 25263,
    "fullName": "SKP2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SKP2 positive indicates the presence of the SKP2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6502,
        "geneSymbol": "SKP2",
        "terms": [
            "SKP2",
            "FBL1",
            "FBXL1",
            "FLB1",
            "p45"
        ]
    },
    "variant": "positive",
    "createDate": "08/19/2016",
    "updateDate": "08/19/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) induced cell cycle arrest, inhibited growth of skin squamous cell carcinoma cells through inhibition of Skp2 expression and signaling in culture (Cancer Res 2017;77(13 Suppl):Abstract nr 2108).",
            "molecularProfile": {
                "id": 26070,
                "profileName": "SKP2 positive"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3151,
                "name": "skin squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9585,
                    "pubMedId": null,
                    "title": "Imatinib-induced downregulation of Skp2 inhibits cell growth in human squamous cell ca",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2108.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1598,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SZL-P1-41 decreased Skp2 protein expression, inhibited growth of prostate cancer cell lines through Tp53-independent mechanism in culture and in cell line xenograft models (PMID: 23911321).",
            "molecularProfile": {
                "id": 26070,
                "profileName": "SKP2 positive"
            },
            "therapy": {
                "id": 1932,
                "therapyName": "SZL-P1-41",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1605,
                    "pubMedId": 23911321,
                    "title": "Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23911321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7845,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SZL-P1-41 decreased Skp2 protein expression, inhibited growth of lung cancer cell lines through Tp53-independent mechanism in culture and in cell line xenograft models (PMID: 23911321).",
            "molecularProfile": {
                "id": 26070,
                "profileName": "SKP2 positive"
            },
            "therapy": {
                "id": 1932,
                "therapyName": "SZL-P1-41",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1605,
                    "pubMedId": 23911321,
                    "title": "Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23911321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26070,
            "profileName": "SKP2 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}